Abeona Therapeutics (LTS:0H7R) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0H7R Abeona Therapeutics Inc LTS:0H7R
45 GF Score
Price $7.12
GF Value $19.19
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Abeona Therapeutics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Abeona Therapeutics Quality Rank Related Terms

LTS:0H7R
45GF Score
Abeona Therapeutics Inc LTS:0H7R
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Abeona Therapeutics (LTS:0H7R) Overvalued in 2026?

Based on GuruFocus' analysis, Abeona Therapeutics stock appears to be undervalued. The current stock price of $7.12 is trading 62.9% below its estimated GF Value™ of $19.19. GuruFocus considers Abeona Therapeutics to be Possible Value Trap.

Key valuation signals for LTS:0H7R:

  • Quality Rank:
  • GF Value™: $19.19 vs. price of $7.12 (62.9% below fair value)
  • GF Score™: 45/100 with 8 warning signs

No single metric tells the full story. See the LTS:0H7R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abeona Therapeutics Business Description

Other Exchanges ABEO:USAPCJ:Germany
Address 6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
45GF Score

Get the complete analysis for LTS:0H7R

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.12
Price
$19.19
GF Value